Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions

Blood

Volumn 115, Issue 23, 2010, Pages 4862-4869

  Golder, Mia ^a   Pruss, Cynthia M ^a   Hegadorn, Carol ^a   Mewburn, Jeffrey ^b   Laverty, Kimberly ^a   Sponagle, Kate ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FERRIC CHLORIDE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ALPHA2 INTEGRIN; CHLORIDE; FERRIC ION; TOXIC SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD SMEAR; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC VARIABILITY; HEMOSTASIS; HYDRODYNAMICS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS; TRANSGENE; TYPE 2B VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE; AMINO ACID SUBSTITUTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; MOUSE MUTANT; THROMBOCYTE; THROMBOCYTE ADHESIVENESS;

AMINO ACID SUBSTITUTION; ANIMALS; BLOOD PLATELETS; CHLORIDES; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; HUMANS; INTEGRIN ALPHA2; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; NOXAE; PLATELET ADHESIVENESS; THROMBOCYTOPENIA; THROMBOSIS; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 77954693471     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253120     Document Type: Article

References (29)

1. Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB: candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest. 1991;87(4):1220-1226.
2. Cooney KA, Ginsburg D. Comparative analysis of type 2B von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood. 1996;87(6):2322-2328.
3. Ruggeri ZM. Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost. 2004;2(1):2-6.
4. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost. 2009;7(suppl 1):65-70.
5. Rayes J, Hommais A, Legendre P, et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost. 2007;5(2):321-328.
6. University of Sheffield. ISTH SSC VWF database. www.vwf.group.shef.ac.uk. Accessed October 24, 2009.
7. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526-534.
8. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529.
9. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, Denis CV. Correction of bleeding symptoms in von Willebrand factor deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28(3):419-424.
10. Lenting PJ, de Groot PG, De Meyer SF, et al. Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF. Blood. 2007;109(5):2267-2268.
11. Shi CX, Graham FL, Hitt MM. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med. 2006;8(4):442-451.
12. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol. 2005;23(1):108-116. (Pubitemid 41724633)
13. Pruss CM, Notley CR, Hegadorn CA, O'Brien LA, Lillicrap D. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br J Haematol. 2008;143(4):552-558.
14. Stakiw J, Bowman M, Hegadorn C, et al. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost. 2008;6(1):90-96.
15. Bruno K, Volkel D, Plaimauer B, et al. Cloning, expression and functional characterization of the full-length murine ADAMTS13. J Thromb Haemost. 2005;3(5):1064-1073.
16. Gavins FN, Chatterjee BE. Intravital microscopy for the study of mouse microcirculation in anti-inflammatory drug research: focus on the mesentery and cremaster preparations. J Pharmacol Toxicol Methods. 2004;49(1):1-14.
17. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006;107(10):3902-3906.
18. Ware J, Russell SR, Marchese P, Ruggeri ZM. Expression of human platelet glycoprotein Ib alpha in transgenic mice. J Biol Chem. 1993;268(11):8376-8382. (Pubitemid 23120430)
19. De Luca M, Facey DA, Favaloro EJ, et al. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. Blood. 2000;95(1):164-172.
20. Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol. 2005;12(2):152-159.
21. Szanto T, Schlammadinger A, Salles I, et al. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb Haemost. 2007;98(1):251-254.
22. Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007;15(12):2063-2069. (Pubitemid 350148920)
23. Nurden P, Chretien F, Poujol C, Winckler J, Borel-Derlon A, Nurden A. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol. 2000;110(3):704-714.
24. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from von Willebrand disease type 2B patients. Blood. 2010;105(13)2649-2656.
25. Schmitt A, Guichard J, Masse JM, Debili N, Cramer EM. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp Hematol. 2001;29(11):1295-1302. (Pubitemid 33033306)
26. Lacombe M, d'Angelo G. Etudes sur une thrombopathie familiale. Nouv Rev Fr Hematol. 1963;3:611-614.
27. Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood. 2009;113(14):3348-3351.
28. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111(6):3042-3049.
29. Golder M, Pruss CM, Hegadorn C, et al. Supraphysiological levels of plasma von Willebrand factor do not support primary hemostasis in von Willebrand factor knock-out mice. J Thromb Haemost. 2009;7(suppl 2):1145.